94 related articles for article (PubMed ID: 9016339)
1. Ibogaine: a potent noncompetitive blocker of ganglionic/neuronal nicotinic receptors.
Badio B; Padgett WL; Daly JW
Mol Pharmacol; 1997 Jan; 51(1):1-5. PubMed ID: 9016339
[TBL] [Abstract][Full Text] [Related]
2. Pseudophrynaminol: a potent noncompetitive blocker of nicotinic receptor-channels.
Badio B; Garraffo HM; Padgett WL; Greig NH; Daly JW
Biochem Pharmacol; 1997 Mar; 53(5):671-6. PubMed ID: 9113086
[TBL] [Abstract][Full Text] [Related]
3. Otilonium: a potent blocker of neuronal nicotinic ACh receptors in bovine chromaffin cells.
Gandía L; Villarroya M; Lara B; Olmos V; Gilabert JA; López MG; Martínez-Sierra R; Borges R; García AG
Br J Pharmacol; 1996 Feb; 117(3):463-470. PubMed ID: 8821535
[TBL] [Abstract][Full Text] [Related]
4. Spiropyrrolizidines: a new class of blockers of nicotinic receptors.
Badio B; Shi D; Shin Y; Hutchinson KD; Padgett WL; Daly JW
Biochem Pharmacol; 1996 Sep; 52(6):933-9. PubMed ID: 8781513
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological distinctions between functional nicotinic acetylcholine receptors on the PC12 rat pheochromocytoma and the TE671 human medulloblastoma.
Lukas RJ
J Pharmacol Exp Ther; 1989 Oct; 251(1):175-82. PubMed ID: 2571716
[TBL] [Abstract][Full Text] [Related]
6. The pharmacology of the nicotinic antagonist, chlorisondamine, investigated in rat brain and autonomic ganglion.
Clarke PB; Chaudieu I; el-Bizri H; Boksa P; Quik M; Esplin BA; Capek R
Br J Pharmacol; 1994 Feb; 111(2):397-405. PubMed ID: 7911713
[TBL] [Abstract][Full Text] [Related]
7. Persistent nicotinic blockade by chlorisondamine of noradrenergic neurons in rat brain and cultured PC12 cells.
Reuben M; Louis M; Clarke PB
Br J Pharmacol; 1998 Nov; 125(6):1218-27. PubMed ID: 9863650
[TBL] [Abstract][Full Text] [Related]
8. Catharanthine alkaloids are noncompetitive antagonists of muscle-type nicotinic acetylcholine receptors.
Arias HR; Feuerbach D; Targowska-Duda KM; Jozwiak K
Neurochem Int; 2010 Sep; 57(2):153-61. PubMed ID: 20493225
[TBL] [Abstract][Full Text] [Related]
9. Epibatidine, a potent analgetic and nicotinic agonist.
Badio B; Daly JW
Mol Pharmacol; 1994 Apr; 45(4):563-9. PubMed ID: 8183234
[TBL] [Abstract][Full Text] [Related]
10. Ibogaine selectively inhibits nicotinic receptor-mediated catecholamine release.
Schneider AS; Nagel JE; Mah SJ
Eur J Pharmacol; 1996 Dec; 317(2-3):R1-2. PubMed ID: 8997631
[TBL] [Abstract][Full Text] [Related]
11. NMDA antagonist properties of the putative antiaddictive drug, ibogaine.
Popik P; Layer RT; Fossom LH; Benveniste M; Geter-Douglass B; Witkin JM; Skolnick P
J Pharmacol Exp Ther; 1995 Nov; 275(2):753-60. PubMed ID: 7473163
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationship of ibogaine analogs interacting with nicotinic acetylcholine receptors in different conformational states.
Arias HR; Feuerbach D; Targowska-Duda KM; Jozwiak K
Int J Biochem Cell Biol; 2011 Sep; 43(9):1330-9. PubMed ID: 21642011
[TBL] [Abstract][Full Text] [Related]
13. The "calcium antagonist" TMB-8 [3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester] is a potent, non-competitive, functional antagonist at diverse nicotinic acetylcholine receptor subtypes.
Bencherif M; Eisenhour CM; Prince RJ; Lippiello PM; Lukas RJ
J Pharmacol Exp Ther; 1995 Dec; 275(3):1418-26. PubMed ID: 8531111
[TBL] [Abstract][Full Text] [Related]
14. Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration.
Pace CJ; Glick SD; Maisonneuve IM; He LW; Jokiel PA; Kuehne ME; Fleck MW
Eur J Pharmacol; 2004 May; 492(2-3):159-67. PubMed ID: 15178360
[TBL] [Abstract][Full Text] [Related]
15. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine.
Fryer JD; Lukas RJ
J Pharmacol Exp Ther; 1999 Jan; 288(1):88-92. PubMed ID: 9862757
[TBL] [Abstract][Full Text] [Related]
16. Evidence for roles of kappa-opioid and NMDA receptors in the mechanism of action of ibogaine.
Glick SD; Maisonneuve IM; Pearl SM
Brain Res; 1997 Feb; 749(2):340-3. PubMed ID: 9138735
[TBL] [Abstract][Full Text] [Related]
17. Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration.
Glick SD; Maisonneuve IM; Kitchen BA; Fleck MW
Eur J Pharmacol; 2002 Mar; 438(1-2):99-105. PubMed ID: 11906717
[TBL] [Abstract][Full Text] [Related]
18. 5,8-disubstituted indolizidines: a new class of noncompetitive blockers for nicotinic receptor-channels.
Daly JW; Nishizawa Y; Padgett WL; Tokuyama T; Smith AL; Holmes AB; Kibayashi C; Aronstam RS
Neurochem Res; 1991 Nov; 16(11):1213-8. PubMed ID: 1815137
[TBL] [Abstract][Full Text] [Related]
19. Dextromethorphan and its metabolite dextrorphan block alpha3beta4 neuronal nicotinic receptors.
Hernandez SC; Bertolino M; Xiao Y; Pringle KE; Caruso FS; Kellar KJ
J Pharmacol Exp Ther; 2000 Jun; 293(3):962-7. PubMed ID: 10869398
[TBL] [Abstract][Full Text] [Related]
20. Ibogaine as a glutamate antagonist: relevance to its putative antiaddictive properties.
Skolnick P
Alkaloids Chem Biol; 2001; 56():55-62. PubMed ID: 11705116
[No Abstract] [Full Text] [Related]
[Next] [New Search]
